Sleep apnoea and its impact on public health by Sheldon, T.A. & Wright, J.
Sleep apnoea and its impact on public health
John Wright, Trevor Sheldon
In 1997 we published a systematic review on
the health eVects of obstructive sleep apnoea
and the eVectiveness of treatment with CPAP.1
This generated much controversy and consid-
erable correspondence. About half the letters
received by the authors suggested that the
paper was just stating the obvious, the other
half that the paper was completely inaccurate.
To help clarify our findings this paper will dis-
cuss the public health impact of sleep apnoea
and the rationale behind systematic reviews.
In recent years several traditional style
reviews in leading medical journals have
suggested the importance of sleep apnoea.2–4
These have claimed that sleep apnoea causes
premature death, hypertension, heart disease,
stroke, pulmonary hypertension, and road traf-
fic accidents. The high prevalence of 2–4% of
the middle aged population5 led an editorial
writer in theNew England Journal of Medicine to
claim that the “staggering” impact of sleep
apnoea was as big a public health hazard as
smoking.2 If so, sleep apnoea would clearly be
of major public concern.
The problem with traditional reviews is that
they can be haphazard, biased and reflect the
personal prior beliefs or interests of individual
reviewers.6 Systematic reviews apply strict
scientific criteria in an attempt to reduce this
bias. They provide a more objective approach
to summarising the large number of biomedical
research papers and allow us to identify gaps in
the research. In addition, systematic reviews
can help increase understanding about the
generalisability, consistency, and precision of
results of individual trials. This is not the same
as “evidence based medicine” but they can
inform individual clinical decisions as well as
health policy.
Like all good science, systematic reviews are
based on rigorous methodology. This includes:
(1) construction of a clearly focused question;
(2) explicit and thorough search of the
literature including non-English language pa-
pers and the “grey” literature (conference
abstracts, reports), as well as contact with
known experts in the field to identify relevant
studies; (3) application of explicit inclusion and
exclusion criteria; (4) appraisal of the
methodological quality and the results of indi-
vidual studies using clear criteria; (5) summary
of the results incorporating suYcient detail for
readers to make up their ownminds about their
interpretation; (6) recommendations or con-
clusions that are clearly based on the evidence
presented in the review and explicit statement
of values.
Assessment of public health implications
of sleep apnoea
From a public health perspective, it is neces-
sary to answer four key questions to provide
patients with an equitable and eVective health
service: What is sleep apnoea and how
common is it? Is there a causal link with mor-
bidity and mortality? Are there cost eVective
and acceptable treatments available? How can
we identify patients who will benefit sufficiently
from treatment to justify the resources used?
WHAT IS SLEEP APNOEA AND HOW COMMON IS IT?
Even with the first question we run into some
confusion and uncertainty. Until recently a
common definition used an apnoea/hypopnoea
index (AHI) of greater than 15. However,
population based studies in the USA and Aus-
tralia have found that 10–20% of middle aged
men have sleep apnoea according to this
criterion.5 7 8 Also, there is poor correlation
between AHI and symptoms of sleepiness. For
example, in one epidemiological study the
prevalence of excessive daytime sleepiness was
found to be 41% in people with sleep
disordered breathing, but this was not signifi-
cantly greater than in those without sleep
disordered breathing where the prevalence was
37%.8
Excessive daytime sleepiness is thus very
common, as is having an AHI of more than 15.
By chance, therefore, many people will have
both, even without there being a causal
relationship between sleep apnoea and sleepi-
ness. In addition, many patients with major
symptoms of sleepiness caused by sleep apnoea
have an AHI of less than 15. A definition which
incorporates apnoeas, hypopnoeas, upper air-
way resistance, and symptoms of daytime
sleepiness has replaced the arbitrary and
narrow earlier definition. However, once
sleepiness becomes integral to the definition,
we cannot discuss the causal relationship
between sleep apnoea and sleepiness as this is
now tautological. It also creates uncertainty as
to how we classify severity of disease. Further-
more, in elderly populations the prevalence of
sleep disordered breathing has been found to
be between 20% and 60%, making it almost
abnormal not to have it.9
Definitional uncertainties create great diY-
culty when we come to consider the possible
population impact and the likely cost of an
equitable health service which will meet the
health needs of a population. Importantly,
definitions are probably more sensibly devel-
oped in the context of the impact of treatments
on length and quality of life.
IS THERE A CAUSAL LINK BETWEEN SLEEP APNOEA
AND MORBIDITY AND MORTALITY?
We know from people’s personal experience,
and from observing the disruption to sleep that
accompanies apnoeas, that sleep apnoea can
cause sleepiness. This is the main reason why
patients are referred for investigation and
treatment. Our systematic review set about to
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investigate whether the claims being made
about the eVect of sleep apnoea on physical
morbidity and mortality were accurate.
In assessing the evidence for causality we rely
on a number of defined criteria as follows: (1)
temporal relationship, (2) strength of associ-
ation, (3) dose response, (4) consistency in dif-
ferent studies, (5) biological plausibility, and
(6) cessation of exposure. These are illustrated
by the relation between smoking and lung can-
cer. Lung cancer has been shown to follow
exposure to smoking, the association is strong
(measured by relative risk or odds ratio), the
more a person smokes the greater their risk of
developing cancer, the relationship is found
consistently in diVerent studies, biological
plausibility follows from our knowledge about
carcinogens in tobacco smoke, and the risk of
developing lung cancer (or heart disease)
declines after quitting smoking.
When considering studies which explore
causal relationships, three other important
issues must be considered in assessing their
methodological quality—bias, chance, and
confounding. These issues arise due to weak-
nesses in the design or conduct of research
studies. Sources of bias include: (1) selection
bias when the inclusion of patients depends in
some way on the exposure of interest (in this
case sleep apnoea); (2) surveillance bias when
more careful monitoring of individuals catego-
rised with sleep apnoea results in picking up
more disease; (3) classification bias due to sys-
tematic errors in the categorisation of disease
or exposure; (4) information bias which
includes interviewer bias, recall bias, non-
response bias, and bias in abstracting data.
The role of chance as an explanation for
associations between conditions and outcomes
can be minimised by ensuring adequate power
through large enough sample sizes and can be
explored by statistical analysis.
The third key problem in epidemiological
studies is that of confounding, when the
observed association is not causal but is medi-
ated through a third independent factor.
Important confounding factors to be consid-
ered in studies of sleep apnoea include obesity
(measured by body mass index or, as a more
accurate marker of central obesity, collar size or
girth/height ratio), age, alcohol, and smoking.
The systematic review1 identified 54 epide-
miological studies investigating the eVects of
sleep apnoea. Most were poorly designed and
only weak or contradictory evidence was found
of an association between sleep apnoea and
hypertension, mortality, cardiovascular dis-
ease, pulmonary hypertension, and stroke. For
example, when we assess the studies looking at
the link with hypertension using the criteria for
evidence of causation we find: (1) all 18 studies
reviewed were cross-sectional and therefore
unable to define the temporal relationship—
that is, that sleep apnoea preceded the
development of hypertension; (2) the relation-
ship was generally weak (as measured by odds
ratios near 1), particularly in comparison to
other risk factors such as obesity and age;(3)
the dose response relationship was contradic-
tory, with such relationship being found in four
studies and not in five; (4) there was poor con-
sistency between studies with only eight of 18
showing an association with daytime hyperten-
sion; (5) there was biological plausibility—
acute spikes in blood pressure accompany
apnoeas. However, nocturnal blood pressure is
lower than daytime blood pressure and the
relationship between these acute spikes and
hypertension or vascular morbidity has not
been established; (6) bias was inadequately
dealt with in some studies which used selected
groups and single blood pressure measure-
ments as a marker of hypertension. Adjustment
for confounding factors such as obesity, age,
diet, salt intake, exercise, alcohol intake, and
smoking was inadequate; (7) the two controlled
intervention studies that examined the eVect of
CPAP failed to show any benefit after treat-
ment (cessation) of sleep apnoea.
One consequence of the inconsistency be-
tween studies is that, in conventional reviews of
the relationship between sleep apnoea and
hypertension, authors can subsequently quote
those studies which support their own preju-
dice.
Even in studies which looked at a link with
road traYc accidents, the evidence, though
stronger, was inconclusive. We concluded that,
given the state of our knowledge, the impact of
sleep apnoea on public health had been
exaggerated.
ARE THERE EFFECTIVE TREATMENTS AVAILABLE?
Clinicians are generally enthusiastic about
their work and believe that what they are doing
is best for their patients. To think otherwise
would be unethical. However, this is not
usually a suYcient basis for assessing the best
treatment.
CPAP
CPAP is the most widely established and
accepted treatment. There are some examples
where the eVects of a clinical condition are so
great, the natural history so well known, and
the eVect of a treatment so large and obvious
that controlled trials are not really necessary to
demonstrate benefit or harm. This may be the
case with very severe sleep apnoea but most
patients do not fall into this category, and clini-
cal observation alone is insuYcient to provide a
reliable estimate of size of benefit correspond-
ing to diVerent degrees of severity. It is
therefore unwise for clinicians who see severe
cases to generalise their observations to a wider
clinical population. Good randomised control-
led trials are needed to evaluate the benefits of
treatment for these patients.
Our review1 assessed the 45 identified
experimental studies of CPAP. Thirty nine of
these were simple before and after studies; they
had no control group and so it is not possible to
attribute the eVect to the intervention. Only
one trial was a randomised controlled trial.10
Though a good trial, it was small, and we high-
lighted a number of methodological weak-
nesses. These were not nasty criticisms and, in
fact, some of the weaknesses identified were
likely to have led to an underestimate of eVec-
tiveness of CPAP. The main criticism was the
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lack of a comparable placebo (a pill was used).
We know that the placebo eVect is very power-
ful, and we know so little about how it works
that to make presumptions about it would be
unwise. For example, the presence of a wire
mesh used in the treatment of incontinence has
been shown to change sleep patterns11 and pla-
cebo treatment is able to lower nocturnal blood
pressure.12 Despite a large number of poorly
designed studies, we concluded that the
evidence strongly suggests that CPAP is
eVective in reducing sleepiness, probably
mostly in patients with severe sleep apnoea.
Our findings were echoed in nine out of 10
summary recommendations from a recent
report by the Australian Medical Research
Council.13 It too recommended long term pro-
spective studies into morbidity and mortality
from sleep apnoea and randomised controlled
trials to establish the benefit of CPAP to those
patients with mild or moderate sleep apnoea
(the majority of patients). The authors con-
cluded, like us, that there was strong evidence
for the eVectiveness of CPAP in patients with
severe disease. They used the results of a meta-
analysis of before and after studies to recom-
mend thresholds of the AHI above which
patients should receive treatment. However,
before and after studies are subject to selection
bias, reporting bias, regression to the mean,
temporal changes, and learning eVects and, in
our view, the validity of this rather unusual
meta-analysis is questionable.
Surgery
A diVerent systematic review of uvulopharyngo-
palatoplasty and other surgical treatments con-
cluded that, at best, the operation was eVective
in less than half of patients.14 In addition, there
was no valid method of identifying pharyngeal
narrowing or collapse to predict which patients
would benefit. There were no randomised
controlled trials of this treatment and the studies
that had been conducted were methodologically
weak, had small sample sizes (a mean of 21), and
poor validity and comparability of the outcomes
used to evaluate eVectiveness.
Oral appliances
As well as many before and after studies, there
have been three randomised controlled trials
evaluating anterior mandibular positioning
devices in comparison with CPAP. These have
included 72 patients, more than had been
studied in trials of CPAP alone.15–17 They
showed a greater reduction in AHI than with
CPAP, and significant improvement in sleepi-
ness with both treatments. It is noteworthy that
there was a strong patient preference for oral
appliances in these trials. However, there have
not been suYciently rigorous comparative
trials to reach reliable clinical conclusions.
Treating obesity
Most patients with sleep apnoea are obese. The
association between severity of disease and
obesity is very strong and consistent. From our
understanding of the pathophysiology and the
role of fat deposits around the upper airway,
this association is causal. Losing weight not
only improves sleep apnoea, but can cure it.18
So, for most patients sleep apnoea is a
symptom of obesity and it is common sense
that, where possible, we should treat the
underlying cause rather than the symptom.
This is particularly true from a public health
perspective since the causal association be-
tween obesity and vascular disease is strong
and well established. Not only can we reduce
sleep apnoea by treating the subject’s obesity,
but also we can reduce the risk of heart disease
and stroke. This approach could improve the
health of the population as well as of the indi-
vidual.
Unfortunately there are no magic pills,
machines, or operations to treat obesity.
Doctors tend to be nihilistic about getting
patients to lose weight. It is not surprising that
common advice to “go away and lose weight”
rarely works. However, there are eVective
interventions to reduce obesity and these have
been highlighted in recent reports from the
NHS Centre for Reviews and Dissemination
and the Royal College of Physicians.19 20 These
include cognitive therapy—including cue
avoidance and behavioural therapy
techniques—providing accurate nutritional
and exercise advice, meal plans, weight charts,
and extended contact with a therapist. How-
ever, it is unlikely that those who are usually
involved in first line treatment of sleep apnoea,
such as respiratory physicians, have suYcient
training or experience to treat obesity eVec-
tively.
What research do we need?
Sleep apnoea, depending on the definition, is
common and its impact on the health of the
public is therefore potentially significant. How-
ever, there is much we need to clarify before we
can justify claims for widespread investment in
sleep services. We need long term prospective
studies to investigate the impact of sleep
apnoea on morbidity and mortality. We need
well designed large randomised controlled
studies to determine not only the eVectiveness
of CPAP and other treatments for sleep
apnoea, but also to define better which patients
benefit from CPAP, by howmuch, at what cost,
and how they may be identified. We need simi-
lar high quality evaluations of other treatments.
The results of this research are likely to be
more reliable if those responsible for the design
and conduct are truly uncertain of the
answers—that is, in genuine equipoise—so as
not to introduce biases, either consciously or
unconsciously.
Competing priorities
We share concerns over the way in which some
health authorities have interpreted the results
of our review rather simplistically. However,
open debate is what is needed and this should
not be censured for fear of hearing what we do
not want to hear. The response of some of the
enthusiasts for CPAP to our review, rather than
promoting the cause of patients with sleep
apnoea, creates the impression that they are not
amenable to a considered approach.
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The health service in the UK has strictly
limited resources and there is no shortage of
competing priorities and new medical tech-
nologies. Funding eVective sleep services may
mean less resources to treat patients with
asthma, chronic lung disease, or lung cancer.
To make these decisions we need reasoned
argument based on evidence of cost eVective-
ness and not selective opinion.
Sleep disordered breathing is a relatively new
field and our understanding of it is in its
infancy. If we look at other common diseases
such as coronary heart disease and the
eVectiveness of thrombolysis, aspirin, angio-
plasty, and coronary artery bypass surgery we
find trials of hundreds or thousands of patients.
These studies tell us which patients benefit,
how great this benefit is, and what the costs of
treatment are—the questions that need to be
answered for sleep apnoea. We should not be
surprised then when recommendations for
whole new services for sleep disordered
breathing on the basis of trials with only 30
patients encounter some resistance.
Some of the gaps that we identified in our
review are being addressed and we look
forward to the results of prospective cohort
studies and further randomised controlled
trials of CPAP, some of which are currently
underway. These will help us to make rational
and informed decisions about the provision of
sleep services in the UK.
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